Daily Sepsis Research Analysis
Analyzed 25 papers and selected 3 impactful papers.
Summary
Today’s most impactful sepsis-related research spans mechanism-informed antibiotic optimization, antimicrobial safety, and the global epidemiology of maternal infection. The strongest studies show that plasma pharmacokinetics may not reflect tissue antibiotic exposure, flucloxacillin is associated with increased acute kidney injury risk compared with cefazolin, and maternal sepsis burden remains concentrated in low-sociodemographic-index regions.
Research Themes
- Mechanism-informed pharmacokinetic and pharmacodynamic optimization
- Antibiotic-associated acute kidney injury
- Global disparities in maternal sepsis burden
Selected Articles
1. Transporter-Drive Interstitial Tissue Exposure and Pharmacodynamic Response of Meropenem in Sepsis: A Mechanistic PBPK Modeling Study.
This mechanistic physiologically based pharmacokinetic/pharmacodynamic model reproduced plasma and subcutaneous interstitial meropenem exposure in healthy and septic populations. It demonstrated substantial tissue-specific heterogeneity and a dissociation between plasma and interstitial exposure; although maximum dosing increased exposure, antibacterial effects were already near a plateau with standard dosing.
Impact: The study challenges plasma-only therapeutic drug monitoring and the assumption that empiric dose escalation universally improves antibacterial activity. Its transporter-informed framework provides a mechanistic basis for individualized dosing according to sepsis severity, renal function, and target tissue.
Clinical Implications: Routine escalation to maximum meropenem dosing may not provide meaningful additional antibacterial benefit for every patient. Clinical implementation should prioritize individualized dosing strategies that account for augmented renal clearance, septic shock-related renal impairment, and tissue penetration, ideally supported by prospective pharmacokinetic and pharmacodynamic validation.
Key Findings
- The model reproduced observed meropenem plasma and subcutaneous interstitial exposure in sepsis.
- Sepsis and septic shock produced opposing changes in clearance, reflecting augmented renal clearance versus impaired renal function and tubular secretion.
- Standard dosing was predicted to achieve near-plateau antibacterial effects, with minimal additional benefit from routine maximum dosing.
Methodological Strengths
- Integrated transporter-mediated renal secretion, disease-specific physiology, tissue permeability, and pharmacodynamic modeling.
- Validated the model against published plasma and tissue concentration-time data from healthy volunteers and critically ill patients.
Limitations
- The conclusions are based on model simulations rather than a prospective clinical dosing trial.
- The pharmacodynamic predictions relied on published bacterial models for Escherichia coli and Klebsiella pneumoniae and may not represent all pathogens or infection sites.
Future Directions: Prospective studies should validate tissue-based exposure predictions, identify patients who benefit from therapeutic drug monitoring, and test adaptive meropenem dosing algorithms across sepsis phenotypes and infection sites.
A whole-body mechanistic PBPK model for meropenem (MPN) was developed in PK-Sim and validated using published plasma and tissue concentration-time data in healthy volunteers and critically ill patients. Renal elimination was implemented as glomerular filtration plus active tubular secretion (basolateral uptake via OAT3 with apical efflux), and non-renal clearance via DHP-mediated hydrolysis. The model was scaled to sepsis or septic shock by incorporating disease-specific physiological changes and optimizing OAT3 activity and tissue permeability to reproduce observed variability.
2. Acute kidney injury in Staphylococcus aureus bacteraemia: a multicentre cohort study of incidence, timing, recovery and associations with antibiotic treatment.
Among 1,408 adults with Staphylococcus aureus bacteraemia, 34.3% developed acute kidney injury, usually early after the index blood culture. Acute kidney injury was more frequent with flucloxacillin than cefazolin after adjustment, while lowering the initial flucloxacillin dose was not associated with reduced risk, timing, or severity.
Impact: This large multicentre cohort provides clinically actionable evidence about the timing, reversibility, and antibiotic associations of acute kidney injury during serious bloodstream infection. The findings support closer early renal surveillance and informed antibiotic selection rather than relying on dose reduction alone to mitigate nephrotoxicity.
Clinical Implications: Renal function should be monitored particularly closely during the first days after diagnosis of Staphylococcus aureus bacteraemia. When clinically appropriate, cefazolin may be considered as an alternative to flucloxacillin in patients at elevated renal risk, while dose reduction of flucloxacillin alone should not be assumed to prevent acute kidney injury.
Key Findings
- Acute kidney injury occurred in 483 of 1,408 patients, representing 34.3% of the cohort.
- Acute kidney injury occurred more frequently with flucloxacillin than cefazolin: 35.2% versus 20.2%, with adjusted odds ratio 2.37.
- Most acute kidney injury episodes occurred early, and 30-day recovery declined from 81.7% in stage 1 to 50.5% in stage 3 disease.
Methodological Strengths
- Large multicentre cohort including 1,408 adults with clinically important bloodstream infection.
- Used adjusted regression, time-to-event analysis, and cumulative incidence methods to examine risk, timing, and recovery.
Limitations
- The retrospective observational design cannot establish that flucloxacillin causes acute kidney injury.
- Treatment groups were unequal in size, with substantially fewer patients receiving cefazolin, and residual confounding by illness severity or treatment selection may remain.
Future Directions: Prospective comparative studies should evaluate renal-risk-adapted antibiotic selection, incorporate detailed nephrotoxin exposure and illness-severity measures, and determine whether early switching or therapeutic monitoring reduces clinically important kidney injury.
BACKGROUND AND OBJECTIVES: Staphylococcus aureus bacteraemia (SAB) is associated with high mortality and frequent complications, including acute kidney injury (AKI). Although flucloxacillin has been associated with higher AKI rates than cefazolin, the clinical characteristics of AKI, including severity, timing, recovery and the potential influence of dosing, remain unclear. METHODS: We conducted a retrospective multicentre cohort study across three hospitals in the Netherlands, including adults with SAB treated with cefazolin or flucloxacillin. AKI incidence and severity were compared using adjusted regression analyses. Time-to-event and cumulative incidence analyses were used to evaluate AKI timing and renal recovery.
3. Global burden of maternal sepsis and other maternal infections from 1990 to 2021, with projections to 2050: risk factors and trends.
Using Global Burden of Disease 2021 data, this ecological analysis quantified maternal sepsis and other maternal infection burden across 204 countries and territories from 1990 to 2021 and projected trends to 2050. Low-sociodemographic-index regions continued to experience the highest burden, with malnutrition and iron deficiency important attributable factors, while future mortality trends remained uncertain.
Impact: The study frames maternal sepsis as a persistent global health inequity rather than only an acute hospital-based problem. Its country- and region-level trend analysis can guide prioritization of infection prevention, early recognition, standardized treatment, and nutritional interventions in resource-limited settings.
Clinical Implications: Maternal health programs should strengthen early identification and standardized management of infection and sepsis, particularly in low- and middle-income regions. Antenatal nutritional assessment and correction of malnutrition or iron deficiency should be integrated with infection-prevention and obstetric emergency systems.
Key Findings
- Maternal sepsis and other maternal infections accounted for approximately 10.7% of global maternal deaths.
- Low-sociodemographic-index regions had persistently higher disease burden and slower declines than high-index regions.
- Maternal malnutrition and iron deficiency were major attributable factors in low-sociodemographic-index regions, while projected incidence and disability-adjusted life years declined but mortality trends remained uncertain.
Methodological Strengths
- Used standardized Global Burden of Disease estimates covering 204 countries and territories over more than three decades.
- Combined burden estimation, socioeconomic association analysis, attributable-risk assessment, and ARIMA forecasting.
Limitations
- The ecological design cannot determine individual-level causal relationships or directly evaluate clinical interventions.
- Global Burden of Disease estimates depend on the quality and completeness of country-specific surveillance and modeling assumptions.
Future Directions: Future work should link global estimates with prospective maternal sepsis surveillance, evaluate context-specific prevention and treatment packages, and test whether nutritional interventions and standardized emergency care reduce mortality in high-burden regions.
OBJECTIVES: Maternal sepsis and other maternal infections (MSMI) account for approximately 10.7 % of maternal deaths globally with a significant burden persisting in low-income and middle-income countries. METHODS: Using GBD 2021 data, this ecological analysis extracted incidence, mortality, disability-adjusted life years(DALYs), and their age-standardized rates(ASR) of MSMI globally, across 21 GBD regions, 204 countries and territories from 1990 to 2021. Locally weighted regression and Spearman correlation were used to evaluate associations between MSMI burden and Socio-demographic Index(SDI). Attributable risk burdens were estimated using the GBD comparative risk assessment framework, and the autoregressive integrated moving average(ARIMA) model projected temporal trends.